GW Pharmaceuticals initiates phase 3 study of Nabiximols for multiple sclerosis-associated spasticity

This article was originally published here

Nabiximols, known as Sativex outside of the U.S. and approved for use to treat MS spasticity in over 25 countries, is a complex botanical medicine formulated from extracts

The post GW Pharmaceuticals initiates phase 3 study of Nabiximols for multiple sclerosis-associated spasticity appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply